Sipuleucel-T: immunotherapy for advanced prostate cancer

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249.
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–1597.
   PubMed Web of Science ®Google Scholar
• D’Amico AV Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284(10):1280–1283.
   PubMed Web of Science ®Google Scholar
• Bianco FJ, Dotan ZA, Kattan MW, et al. Natural history of biochemically-recurrent castrate-resistant disease in men treated with maximal androgen blockage for a rising PSA after radical prostatectomy. Paper presented at the American Society of Clinical Oncology Prostate Cancer Symposium, February 17–19, 2005, Orlando, FL.
   Google Scholar
• Burnstein KL. Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy. J Cell Biochem. 2005;95(4):657–669.
   Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276–308.
   PubMed Web of Science ®Google Scholar
• Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168(6):2439–2443.
   PubMed Web of Science ®Google Scholar
• Ernst DS, Tannock IF, Winquist EW, et al. Randomized, doubleblind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21(17):3335–3342.
   Web of Science ®Google Scholar
• Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506–2513.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized double-blind placebo-controlled phase 3 study. Paper presented at the annual meeting of the European Society for Medical Oncology, April 28-May 1, 2010, Milan, Italy.
   Google Scholar
• Ehrlich P. Über den j etzigen stand der karzinomforschung. Ned Tijdschr Geneeskd. 1909;5(1):273–290.
   Google Scholar
• Thomas L. . Discussion of cellular and humoral aspects of the hypersensitive states. In: Lawrence HS, editor. Cellular and Humoral Aspects of the Hypersensitive States. New York, NY: Hoeber-Harper; 1959.
   Google Scholar
• Burnet FM. Immunological aspects of malignant disease. Lancet. 1967;1:1171.
   PubMed Web of Science ®Google Scholar
• Zarour H, DeLeo A, Finn O, Storkus W. Tumor antigens. In: HollandFrei Cancer Medicine. 6th ed. Hamilton, ON: BC Decker; 2003.
   Google Scholar
• Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun. 2006;6:1.
   PubMedGoogle Scholar
• Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–5337.
   PubMed Web of Science ®Google Scholar
• Disis M, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994;54(1):16–20.
   PubMed Web of Science ®Google Scholar
• Hirohashi Y, Torigoe T, Inoda S, et al. The functioning antigens: Beyond just as the immunological targets. Cancer Sci. 2009;100(5):798–806.
   Web of Science ®Google Scholar
• McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate. 2001;47(3):222–229.
   Web of Science ®Google Scholar
• Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 1990;29(5):545–550.
   PubMed Web of Science ®Google Scholar
• Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene. 25;29(8):1093–1102.
   Google Scholar
• Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994;30A(12):1797–1803.
   PubMed Web of Science ®Google Scholar
• Batstone GR, Doble A, Gaston JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin Exp Immunol. 2002;128(2):302–307.
   Web of Science ®Google Scholar
• Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: Evidence of T cell reactivity with normal prostatic proteins. Urology. 1997;50(6):893–899.
   Web of Science ®Google Scholar
• Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis. 2005;26(7):1170–1181.
   PubMed Web of Science ®Google Scholar
• McNeel DG, Nguyen LD, Disis ML. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res. 2001;61(13):5161–5167.
   Web of Science ®Google Scholar
• Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncol Rep. 2004;12(3):601–607.
   Web of Science ®Google Scholar
• Olson BM, McNeel DG. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate. 2007;67(16):1729–1739.
   Web of Science ®Google Scholar
• Saffran DC, Reiter RE, Jakobovits A, Witte ON. Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev. 1999;18(4):437–449.
   Web of Science ®Google Scholar
• Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgendeprivation therapy on the immune system: Implications for combination therapy of prostate cancer. Front Biosci. 2007;12:4957–4971.
   PubMed Web of Science ®Google Scholar
• Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7(3):239–249.
   PubMed Web of Science ®Google Scholar
• Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol. 2010;71(5):496–504.
   Web of Science ®Google Scholar
• Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004;173(10):6098–6108.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kakuma T, Uemura H, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother. 2010;59(7):1001–1009.
   PubMed Web of Science ®Google Scholar
• Karbach J, Neumann A, Atmaca A, et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res. 2011;17(4):861–870.
   PubMed Web of Science ®Google Scholar
• Perambakam S, Hallmeyer S, Reddy S, et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide. Cancer Immunol Immunother. 2006;55(9):1033–1042.
   PubMed Web of Science ®Google Scholar
• Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. J Immunol. 1997;159(7):3113–3117.
   Web of Science ®Google Scholar
• Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004;91(4):688–694.
   PubMed Web of Science ®Google Scholar
• McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27(25):4047–4054.
   PubMed Web of Science ®Google Scholar
• Lubaroff DM, Konety BR, Link B, et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: Safety and immunologic results. Clin Cancer Res. 2009;15(23):7375–7380.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–1105.
   PubMed Web of Science ®Google Scholar
• Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113(5):975–984.
   PubMed Web of Science ®Google Scholar
• Emens LA. GM-CSF-secreting vaccines for solid tumors. Curr Opin InvestigDrugs. 2009;10(12):1315–1324.
   Google Scholar
• Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010;20(3):241–246.
   PubMed Web of Science ®Google Scholar
• Copier J, Dalgleish A. Whole-cell vaccines: A failure or a success waiting to happen? Curr Opin Mol Ther. 2010;12(1):14–20.
   PubMedGoogle Scholar
• Murphy GP, Tjoa BA, Simmons SJ, et al. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate. 1999;39(1):54–59.
   PubMed Web of Science ®Google Scholar
• Olson BM, Frye TP, Johnson LE, et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010;59(6):943–953.
   PubMed Web of Science ®Google Scholar
• Becker J, Olson B, Johnson L, Davies J, Dunphy E, McNeel D. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010;33(6):639–647.
   PubMed Web of Science ®Google Scholar
• Machlenkin A, Azriel-Rosenfeld R, Volovitz I, et al. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother. 2007;56(2):217–226.
   Web of Science ®Google Scholar
• Wang Y, Harada M, Yano H, et al. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother. 2005;28(6):535–541.
   Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xeno-antigen vaccination for prostate cancer immunotherapy. J Immunol. 2001;167(12):7150–7156.
   PubMed Web of Science ®Google Scholar
• Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. J Immunol. 1997;159(7):3113–3117.
   Web of Science ®Google Scholar
• US Food and Drug Administration labeling information – Provenge. 2010. Available at: http://www.fda.gov/downloads/BiologicsBlood Vaccines/CellularGeneTherapyProducts/Approved Products/ UCM210031.pdf. Accessed April 1, 2011.
   Google Scholar
• Laus R, Yang D, Ruegg C, et al. Dendritic cell immunotherapy of prostate cancer: Preclinical models and early clinical experience. Cancer Res Ther Control. 2001;11:1–10.
   Google Scholar
• Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18(23):3894–3903.
   PubMed Web of Science ®Google Scholar
• Takaue Y, Tanosaki R, Tobi su K, et al. Antigen-pul sed dendritic cell therapy for the treatment of hormone-refractory prostate cancer: A phase I trial of APC8015. Paper presented at the 38th annual meeting of the American Society of Clinical Oncology, May 18–21, 2002, Orlando, FL.
   Google Scholar
• Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6(6):2175–2182.
   PubMed Web of Science ®Google Scholar
• Burch P, Croghan G, Gastineau D, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase II trial. Prostate. 2004;60(3):197–204.
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089–3094.
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–3679.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Silverman E. Provenge approval means sensitive coverage decisions. Manage Care. 2010;19(9):31–34.
   Google Scholar
• Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):479–481.
   PubMed Web of Science ®Google Scholar
• Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: Results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007;25(24):3680–3687.
   PubMed Web of Science ®Google Scholar
• Peethambaram PP, Melisko ME, Rinn KJ, et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009;15(18):5937–5944.
   PubMed Web of Science ®Google Scholar
• Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: Towards a new therapy for minimal residual disease. Exp Opin Biol Ther. 2008;8(7):951–968.
   PubMed Web of Science ®Google Scholar
• Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: The need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev. 2008;222:316–327.
   PubMed Web of Science ®Google Scholar
• Gray A, Garcia-Hernandez MD, van West M, Kanodia S, Hubby B, Kast WM. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine. 2009;27:G52–G59.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096–1103.
   PubMed Web of Science ®Google Scholar
• Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006;107(1):67–74.
   PubMed Web of Science ®Google Scholar
• Gregor PD, Wolchok JD, Ferrone CR, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004;22(13–14):1700–1708.
   PubMed Web of Science ®Google Scholar
• Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011;17(4):896–906.
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60(9):2444–2448.
   PubMed Web of Science ®Google Scholar